

## GlaxoSmithKline (UK Ltd) and Health Innovation Manchester Executive Summary

### Health Innovation Manchester and GSK Joint Working: Optimisation of care for people living with COPD in Greater Manchester.

This summary has been written by GSK with consultation and approval from the Joint Working Project Team.

Health Innovation Manchester and GSK are undertaking a Joint Working project. The aims are to:

- Validate the COPD disease registers within participating practices including GOLD staging for each patient.
- Deliver reviews for COPD patients in line with GMMMG ‘COPD Management Plan’. Ensuring effective medicines optimisation in line with the locality prescribing guidelines.
- Align to the GMMMG ‘COPD Management Plan’ to ‘use dry powder inhalers wherever possible to avoid the environmental impact of MDI inhalers’ and the Investment and Impact Fund ‘Help create a more sustainable NHS’ enhanced service where clinically appropriate for patients.
- Ensure appropriate referral to local pulmonary rehabilitation, smoking cessation, oxygen services and members of the MDT where needed.
- Support primary care to conduct guideline level reviews through education.
- Supporting the NHS, where applicable, in achieving NHS England’s priorities according to 2022/23 priorities and operational planning guidance and Core20PLUS5 focus areas e.g. increasing the uptake of Flu and Pneumonia vaccines.

This involves a balance of contributions from both parties with the pooling of skills, experience and resources. The project will run from June 2022 to May 2023.

#### Intended Benefits:

Patients	<ul style="list-style-type: none"> <li>• Full COPD review in line with local guidelines based on GOLD risk stratification to ensure that at risk patients are prioritised for review.</li> <li>• Optimisation of both non-pharmacological &amp; pharmacological management.</li> <li>• Potentially fewer COPD exacerbations, out of hours/A&amp;E visits and hospital admissions.</li> <li>• Better informed about COPD management and treatment options leading to potentially greater concordance with therapy.</li> <li>• COPD managed in accordance with current best practice clinical guidance.</li> <li>• Better experience of the healthcare system – access to a NSHI respiratory Nurse specialist and/or upskilled primary care clinician at their own GP practice.</li> </ul>
NHS	<ul style="list-style-type: none"> <li>• Validation of the COPD register and signposting of patients for further investigation for patients who may not have COPD or may have other co-existing conditions which may remain, as yet, undiagnosed.</li> <li>• Support with patient identification and risk stratification.</li> <li>• Additional nurse resource support.</li> <li>• Guideline implementation resulting in consistent prescribing and non-prescribing recommendations and promoting learning for sustainability.</li> <li>• Insight into COPD population at practice and local healthcare economy level to allow sharing best practice and evaluation of care provision to support clinical governance and support equity of care.</li> <li>• Opportunity to upskill primary care doctors and nurses.</li> <li>• An environment to support the delivery of improved health outcomes for the COPD patient population.</li> <li>• Potential reduction in COPD-related interventions, including hospital admissions.</li> <li>• Prescribing in line with national and local sustainability aspirations where clinically appropriate for patients.</li> </ul>
GSK	<ul style="list-style-type: none"> <li>• Broadening of the professional network.</li> <li>• Demonstrate partnership working.</li> </ul>

## GlaxoSmithKline (UK Ltd) and Health Innovation Manchester Executive Summary

	<ul style="list-style-type: none"><li>• Aligned to the sustainability agenda there may be a potential increase in prescribing of on-formulary DPI products within class if clinically appropriate for patients – which may or may not include GSK products.</li><li>• Expansion of the COPD patient population who are managed according to current clinical and best practice guidelines as a result of the programme.</li><li>• Increase in the appropriate use of medicines licensed for COPD aligned to local guidance, will likely increase the prescribing of GSK products as well as those of other pharmaceutical companies.</li><li>• Better understanding of the challenges faced by the NHS in delivering high-quality patient services and care.</li><li>• Helps GSK to live its value of being a patient-focussed company.</li></ul>
--	---